Aim: Myokines are peptides released by the skeletal muscle, and have gained popularity as potential biomarkers for sarcopenia. Irisin is a recently identified myokine, but its role in pathological sarcopenia remains unclear. We investigated the validity and accuracy of circulating irisin levels as a potential biomarker for sarcopenia.
Introduction
Sarcopenia refers to the gradual loss of skeletal muscle mass and function that can occur as part of the normal physiological aging process or secondary to pathological conditions that lead to physical disability and frailty. 1, 2 The association between sarcopenia and cardiovascular and metabolic disease morbidities has been investigated. 3, 4 In a clinical setting, the neglect of early-stage sarcopenia is an important issue that must be addressed, because the effects can be reversed through enhanced physical activity. 5 Therefore, early detection of sarcopenia in older adults can reduce the long-term care needs of this population, as well as improve their quality of life with reduced morbidity and mortality. To this end, the Asian Working Group for Sarcopenia recommends routine screening for sarcopenia for people aged older than 60 or 65 years. 6 Multiple studies have sought to identify effective methods to detect early sarcopenia using dual-energy X-ray absorptiometry, magnetic resonance imaging, computed tomography and physical performance tests. Several blood indicators have also been proposed as biomarkers for muscle atrophy and dysfunction; however, these still have critical limitations, including a lack of muscle specificity, feasibility, functional correlation and interference by proinflammatory responses that can stimulate their release. [7] [8] [9] The adipose tissue and muscle synthesize and release molecules that are involved in the systemic inflammatory response and control of metabolism. Pro-inflammatory adipokines secreted from white adipose tissues promote insulin resistance and atherosclerotic changes in obese individuals. 10 This is in contrast to myokines released from the skeletal muscle, which are thought to improve glucose and lipid metabolism, and reduce the risk of chronic metabolic disease. 11 Recently, irisin has been identified as a novel myokine that accelerates the beigeing and browning of adipocytes, 12 and stimulates glucose uptake and fatty acid oxidation. 13 Irisin is a 112-amino acid peptide that is proteolytically cleaved and secreted from the fibronectin type III domain containing protein 5, which is predominantly expressed in the skeletal muscle. 14 Notably, irisin levels are positively correlated with muscle mass and strength. 15 Accumulating evidence has shown that circulating irisin levels increase with exercise training in humans and animals, thus implying that irisin secretion depends on muscle status. 16 However, the correlation between irisin levels and sarcopenia in patients of different ages and sexes has not been clearly elucidated.
Here, we investigated the association between serum irisin concentrations and risk factors for age-related muscle atrophy and/or weakness by carrying out a crosssectional analysis on community-dwelling Koreans. The results of the present study provide reliable evidence to support the potential utility of circulating irisin levels as a novel biomarker for sarcopenia.
Methods

Participants
We carried out a cross-sectional study on 715 Korean participants aged 18-90 years who visited the Center for Exercise Medicine in W City, Korea, from January 2012 to April 2014. Circulating irisin levels were measured using a multistage stratified sampling method. Participants with a history of specific muscle diseases, peripheral vascular disease, intermittent claudication, central and peripheral nervous system disorders, cachexia, active diagnosis of diabetes mellitus, myocardial infarction, stroke, liver disease, on dialysis or long-term steroid therapy, and/or actively receiving treatment for cancer or severe infection (excluding short-term antibiotic therapy) were excluded from enrollment. All participants provided written informed consents. The study was approved by the ethical committee of Yonsei University Wonju College of Medicine, Wonju, Korea (YWMR-12-0-050), and was carried out in compliance with the Helsinki Declaration principles. , respectively. Waist circumference was measured at the midpoint between the lower rib margin and iliac crest, and was used to calculate the waist-to-height ratio (WHtR). Body composition variables were measured by multifrequency bioelectrical impedance analysis (Inbody 720; Biospace, Seoul, Korea) following a standard protocol 17 that has been proven to be an appropriate alternative to dualenergy X-ray absorptiometry. 18 
Anthropometric and body composition measurements
Measurement of sarcopenia-related parameters
Skeletal muscle mass was defined as the sum of appendicular lean mass (ALM) from all four limbs and was adjusted for height squared in meters (ALM/height 2 ). Handgrip strength (HGS) was measured by a dynamometer (Takei Scientific,Tokyo, JPN). Both hands were measured twice, and the maximum value of either hand was analyzed.
Definitions of clinically meaningful skeletal muscle atrophy and weakness Skeletal muscle atrophy was defined as ALM/height 2 <7.0 kg/m 2 for men and <5.7 kg/m 2 for women. 6 Weakness was defined as HGS <26 kg for men and <18 kg for women. 6 By combining these criteria, all participants were classified into the following three groups according to sex: (i) normal (neither muscle atrophy nor weakness); (ii) pre-sarcopenia (either muscle atrophy or weakness); and (iii) sarcopenia (both muscle atrophy and weakness). Although pre-sarcopenia is typically defined by the presence of muscle atrophy alone, we classified the conditions of those who have either muscle atrophy or weakness as pre-sarcopenia based on the preliminary result that there were no differences in physical and functional performances in both adults and older adults.
Measurement of serum irisin concentrations
Blood was drawn from a forearm vein and collected in EDTA tubes. Tubes were immediately centrifuged for 10 min at 1000 g at 4°C, and serum samples were collected and stored at À80°C until analysis. Serum irisin concentrations were measured using a commercially available enzyme-linked immune sorbent assay kit (AG-45A-0046PP-KL01; Adipogen, Seoul, Korea) with intra-and interassay variation coefficient of <10%.
Statistical analysis
Continuous variables are presented as mean plus standard deviation or standard error. All data values were normally distributed. Multiple comparisons among the subgroups were carried out using the one-way analysis of variance (ANOVA) with subsequent Bonferroni post-hoc analysis. Multinomial (polychotomous) logistic regression analysis was carried out to determine the association between circulating irisin levels and muscle condition using the classification of sarcopenia status as the dependent variable (ordered as normal, pre-sarcopenia and sarcopenia) and irisin level as the covariate. The association between circulating irisin levels and muscle condition was expressed as odds ratios (OR) and 95% confidence intervals (CI). Two models were fitted with the unadjusted model. Model 1 included covariates, adjusting for sex and age, and model 2 additionally included covariates, adjusting for BMI and WHtR. In both the unadjusted and adjusted models, the normal group acted as a reference group for the pre-sarcopenia and sarcopenia groups. A receiver operating characteristic (ROC) analysis was carried out to validate the performance of circulating irisin as a biomarker to discriminate between the normal participants and those with sarcopenia (or presarcopenia). The optimum cut-off values to predict incident sarcopenia were determined by the Youden's index for the overall population, and separately for men and women. The areas under the ROC curves (AUC) were compared using the PROC logistic analysis in SAS (SAS Institute, Cary, NC, USA). A P-value <0.05 was considered statistically significant, and all statistical analyses were carried out using the SPSS 20.0 (IBM, Armonk, NY, USA) or SAS version 9.2 (SAS).
Results
The distribution of the study participants was similar among the age groups: 32% young-aged (age 18-34 years; 48% men, 52% women), 31% middle-aged (age 35-64 years; 46% men, 54% women) and 37% elderly (ages ≥65 years; 43% men, 57% women).
Circulating irisin levels were negatively correlated with age in both men and women, as well as in the total participants (Table 1 ; Supplementary Fig. 1a ). In addition, mean circulating irisin levels in the elderly were significantly lower compared with those of the young and middle-aged adults in both sexes (Supplementary Fig. 1b) . The mean circulating irisin levels were remarkably lower in the middle-aged women than in the young women; however, this difference was not observed in men.
The characteristics of the study participants classified by sarcopenia-related parameters and sex are described in Table 2 . As expected, the mean absolute and relative values of muscle mass and strength were significantly lower in the elderly, whereas WHtR and body fat percentage were higher in the elderly than in the young and middle-aged adults in both sexes (Supplementary Table  1 ). The prevalence rates of pre-sarcopenia and sarcopenia were 16.8% (11.4% men, 21.3% women) and 4.3% (3.7% men, 4.9% women), respectively (Table 3) .
Circulating irisin levels were positively correlated with ALM/height 2 (men, r = 0.275; women, r = 0.321) and HGS (men, r = 0.219; women, r = 0.312) in both sexes (all P < 0.01; Table 1 ). These positive associations were consistently observed through the logistic regression analyses among the overall study participants, even after adjusting for sex, age and fat indices (Supplementary Table  2 ). When the participants were classified by muscle condition, the mean circulating irisin level was significantly lower in the pre-sarcopenia and sarcopenia groups than in the normal group in both sexes (Fig. 1) . Notably, the mean irisin level was significantly lower in the sarcopenia group than in the pre-sarcopenia group in Table 3 shows that a low level of circulating irisin was strongly associated with pre-sarcopenia and sarcopenia, even after adjusting for sex and age (model 1), and making additional adjustments for BMI and WHtR (model 2). We carried out the ROC analysis to validate the predictive effect of circulating irisin levels for sarcopenia. Figure 2 shows the ROC curves of circulating irisin levels to discriminate between the normal individuals and those with sarcopenia or pre-sarcopenia. For predicting sarcopenia, the AUC of the unadjusted irisin levels was 0.873 in men and 0.685 in women. At maximal sensitivity and specificity, the optimal cut-off values of serum irisin concentrations (rounded to two decimal places) were <1.00 μg/mL for men (92% sensitivity and 83% specificity) and <1.16 μg/mL for women (77% sensitivity and 67% specificity). In further analyses, we used the PROC logistic to statistically compare the discriminating potentials between the unadjusted circulating irisin levels and adjusted models. The adjusted models showed notable improvement in the discriminatory potential for sarcopenia in both men and women (good to high accuracy in men; moderate to good accuracy in women), even though they were not significantly greater than the unadjusted circulating irisin level. Interestingly, these findings were observed in predicting pre-sarcopenia, even though the adjusted models had significantly higher accuracies compared with the unadjusted models.
Discussion
As described in previous studies, the present study population displayed age-dependent muscle atrophy and weakness, decline in BSA and an increase in obesityrelated variables, such as WHtR and body fat percentage. 19, 20 We also observed correlations between serum irisin concentrations and age-related changes in the anthropometric and body composition parameters. BSA is a commonly used indicator of metabolic mass in physiology and clinical medicine that takes into account variations in body size and composition that are often neglected by simpler measurements, such as bodyweight. A recent study showed that BSA is correlated with the skeletal muscle area in healthy adults, and thus is a potential predictive variable for sarcopenia. 21 In the present study, we found consistent positive correlations between BSA and ALM and HGS. Serum irisin level was also positively associated with BSA. Previously, there have been controversies regarding the relationship between circulating irisin levels and aerobic capacity in the skeletal muscle. 22, 23 However, multiple studies have concluded that circulating irisin levels are related not only to lean mass, 14 but also to muscle strength and function, 15, 16 which is consistent with our own findings showing that circulating irisin levels were associated with ALM and HGS. It has been shown that irisin levels are closely related to the level of circulating insulin-like growth factor 1, which is known to contribute to muscle hypertrophy. 14, 24 All of these findings suggest that there is a positive link between irisin and muscle physiology and metabolism, and suggest a potential regulatory role for irisin. 15, 25 Although circulating irisin is mainly released by the muscle tissues, adipocytes also contribute to approximately one-quarter of total secreted irisin levels. 26 Therefore, we carried out a multinomial logistic regression analysis to rule out the contribution made by the adipocytes. Even after adjusting for indices of body fat, the statistically significant negative association between irisin levels and muscle atrophy and/or weakness still remained. Furthermore, the present results showed that both WHtR were negatively associated with irisin levels. These results confirm that serum irisin levels were more dependent on the muscle rather than the adipose tissues.
There is a gradual loss of muscle mass and function that begins in middle adulthood. 19 The present results Figure 1 Comparisons of the circulating irisin levels in the subgroups defined according to sarcopenia class in the 715 study participants. Pre-sarcopenia was classified as the presence of either muscle atrophy (appendicular lean mass/height 2 <7.0 kg/m 2 for men and <5.7 kg/m 2 for women) or weakness (handgrip strength <26 kg for men and <18 kg for women). Sarcopenia was defined as muscle atrophy plus weakness. Values are presented as mean ± standard error. ANOVA was used followed by the post-hoc test using the Bonferroni method. *P < 0.05, **P < 0.01, ***P < 0.001 versus the normal group, respectively; †P < 0.05 versus the pre-sarcopenia group. Figure 2 Receiver operating characteristic (ROC) curves for the prediction of pre-sarcopenia and sarcopenia. ROC curves of the circulating irisin levels with or without adjustment for confounding factors. In the PROC logistic analysis using SAS. *P < 0.05, **P < 0.01, compared with the area under the receiver operating characteristic curve (AUC) of the unadjusted irisin, respectively. BMI, body mass index; CI, confidence interval; WHtR, waist-to-height ratio. showed that the age-dependent decrease in irisin levels was more pronounced in middle-aged women compared with men. In addition, the female participants partly showed slightly higher irisin levels than the male participants within the subgroups of young-age and sarcopenia, even though there was no sex difference in the circulating irisin level among the total population in the present study. These aspects led us to calculate a separate cut-off value according to sex. Consequently, our findings showed that the cut-off value of irisin concentration was also marginally higher in women than in men for predicting sarcopenia. The difference in the circulating irisin levels between mature men and women is still debated. 23, 25 According to recent studies, women consistently showed modestly higher levels of circulating irisin than age-matched men, regardless of age and metabolic disorder. [27] [28] [29] These studies suggested that sexual dimorphism exists for circulating irisin levels, even though women commonly indicate a disadvantageous body composition with a lower lean and higher fat proportion. The plausible reasons for the divergent findings between the sexes were sex steroid hormones and probably their interactions. 14, 27, 28 In particular, estradiol as an anabolic steroid has been positively correlated with irisin levels in female populations, and might influence irisin levels through anabolic pathways to mediate muscle mass and upregulate irisin expression.
14 Such sex difference in the cut-off values in the present study is likely to be attributable to sexual dimorphism, even though we could not show the causal relationship between sex steroid hormones and irisin.
Despite the potentiality of circulating irisin as a biomarker for sarcopenia, the validity of its predictive effect in women is lower than that in men. Differences in body composition between the sexes might also confound the relationship between irisin and the sarcopenic state. 30 In this respect, the fact that WHtR strongly correlated with body fat mass and its percentage could mean that adjusting for WHtR contributed to a stronger discriminatory potential, especially in women.
With or without adjustment for confounders (sex, age and fat indices), pre-sarcopenia and sarcopenia are meaningfully associated with lower odds of circulating irisin levels, thus implying that circulating irisin could be a useful biomarker for sarcopenia development in old age. In contrast to the present results, another report suggested that serum irisin levels did not vary with muscle mass in a combined analysis of male and female participants who were defined based on the skeletal muscle mass index. 31 However, the cut-off points used in that study seem to be too lenient for defining sarcopenia compared with the recommendations of the Asian Working Group for Sarcopenia, as they did not even include an evaluation of muscle function. In order to adopt a comprehensive operative definition and to overcome ambiguities in sarcopenia syndrome, it is important to avoid relying on a single parameter or technique. 9 According to a recent consensus, the diagnosis and prognosis of sarcopenia should take into account the whole-body or appendicular lean mass in combination with muscle function. 6 The ROC analysis showed that the independent measurement of the circulating irisin levels had a good accuracy for sarcopenia in men, but only moderate accuracy in women. With further analysis, the discriminative capacity could be improved by taking into account confounding factors, such as age and obesity-related parameters. Interestingly, when the irisin levels for age, BMI and WHtR were adjusted, the AUC for the prediction of sarcopenia were 0.942 in men and 0.804 in women, indicating high and good accuracies, respectively. Similar findings were observed for the prediction of presarcopenia, as the discriminatory powers were more accurate than the unadjusted irisin levels (AUC 0.819 in men and 0.790 in women vs AUC 0.641 in men and 0.621 in women, respectively). Such finding is important, as a good biomarker of sarcopenia should detect not only clinically manifested sarcopenia, but also pre-sarcopenic states. 5, 32 The present findings are in concordance with the recommendation of the Biomarkers Definitions Working Group, as we have shown that circulating irisin levels are sensitive to the emerging symptoms of sarcopenia, and are thus useful for the early identification of sarcopenia.
The present study had some limitations. First, the number of participants with both muscle atrophy and weakness was relatively small. Second, we used a multifrequency bioelectrical impedance analysis to assess muscle mass; even though this has been well validated, dualenergy X-ray absorptiometry might be required to further verify these findings. Third, the cross-sectional design of the present study did not allow us to elucidate the causative relationship between circulating irisin levels and sarcopenia. Larger prospective multicenter studies are required to confirm these findings. Despite these limitations, the strength of our study was that, to our knowledge, this is the first study to evaluate sarcopenia based on the combination of muscle mass and function in both sexes in a community-dwelling adult population. In addition, the present study substantiated the validity of serum irisin measurement, and provided a better understanding of the relationship between circulating irisin levels and anthropometric characteristics or agerelated muscle changes.
The present study shows that circulating irisin levels can accurately discriminate between normal and presarcopenic or sarcopenic states, even after adjustments for age and anthropometrics. Therefore, these findings suggest that circulating irisin is a novel potential biomarker for sarcopenia, and might prevent muscle wasting and allow for early intervention for at-risk patients.
Further studies are required to investigate the predictive potential of irisin in patients with severe sarcopenia, as well as in the frail and elderly population.
